NTHI (NeOnc Technologies Holdings Inc.) stock: $4.67, $134.9M market cap, $6.2M cash, $128.7M EV, $134.3M fully diluted market cap. Lead program: NEO100 (Residual, Progressive or Recurrent Grade II or III Meningioma), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Recurrent malignant glioma (Grade IV IDH1-mutant GBM; Grade III IDH1-mutant astrocytoma)(Phase 2)
Status note Lead candidate. Naturally occurring monoterpenoid (POH). Phase 1 safety testing completed; Phase 2a enrollment completed and clinical data collected. Company intends to meet with FDA to discuss design of a potential Phase 3 trial.
Primary and secondary malignant brain cancer (recurrent IDH1 wildtype GBM)(Phase 1)
Status note Designed to enhance CNS penetration and address MGMT-mediated temozolomide resistance. NEO212-01 Phase 1/2 dose escalation completed (MTD reached at 810 mg; RP2D 610 mg). FDA provided CMC clearance to advance to Phase 2 and indicated the program may proceed under the accelerated approval pathway. Planned Phase 2 redesigned to focus on recurrent IDH1 wildtype GBM; Type B end-of-Phase 1 meeting planned.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline
Lead drug
NEO100
Lead indication
Residual, Progressive or Recurrent Grade II or III Meningioma
Pediatric Tumor of CNS; Pediatric Tumor of Brain; Diffuse Midline Glioma, H3 K27M-Mutant
—
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.